However, mithramycin, a clinically anti-tumor antibiotic, has been reported to nonspecifically suppress SETDB1 expression in a dose-dependent manner, which binds to GC-rich regions of genome thus interferes with the association of transcriptional activators at Setdb1 promoters.5 The gene discussed is SETDB1; the disease is neoplasm.